Abstract # 2062 Preliminary Results in 185 Patients Treated with Accelerated Partial Breast Irradiation for Early-stage Breast Cancer

Presenter: Tokita, Kenneth

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

Between February 2003 and June 2008, 175 patients with unifocal AJCC pathological T0, T1, or T2 (up to 3.0 cm), N0 or N1 (up to one positive axillary node) ductal, papillary, colloid, tubular or lobular carcinomas of the breast were treated with post-lumpectomy accelerated partial breast irradiation using iridium-192 high-dose-rate brachytherapy. Tumors were ≥ 0.1 cm from the inked edge of the lumpectomy specimen and had a median Scharff-Bloom-Richardson score of 6/9. Eighty-five percent of the tumors were estrogen-receptor positive. Patientsí ages ranged from 34 to 94 years (median, 60 years). One hundred and thirty-eight patients were treated with a MammoSite balloon catheter (MammoSite Radiation Therapy System; Cytyc Corporation, Marlborough, MA) and 37 patients were treated with multi-catheter brachytherapy. Patients with small lumpectomy cavities were typically treated with multi-catheter brachytherapy using 4-16 (median, 7) catheters. A dose of 34 Gy was delivered in 10 fractions bid over 5-10 days prescribed to a depth of 1 cm. Prophylactic antibiotics (usually cephalexin) were administered during brachytherapy. Tamoxifen and/or chemotherapy were allowed beginning at least 2 weeks after brachytherapy. Median follow-up was 26 months. Local control, disease-free, and overall survival were calculated according to the Kaplan-Meier method.